UCB SA (0NZT) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of UCB SA €212, price €205, upside +3.4%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
UCB SA
0NZT · LSENeutralThe stock looks roughly fairly valued with average quality.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
How to read this chart
60‑month range €64.56 – €283.89 · fair‑value band €149.16 – €270.42 · the €204.95 price screens below the €211.89 fair value. Dashed = 300-day average. As of Sep 29, 2026.
Company profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
Show more
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Stock analysis
UCB SA (0NZT) currently trades at €204.95, while our model-based Fair Value estimate is €211.89, so the stock looks roughly fairly valued today (gap 3.3%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €194.93 per share, and 5 of the 25 models we run sit above the €204.95 price.
Bear case: the Dividend Discount group reads lowest at €44.30, and 20 of the 25 models stay below the price. Evidence for this calculation is low.
Scenario range: €149.16 (bear) to €270.42 (bull), the price of €204.95 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
UCB SA reported revenue of €5.3B in FY2020 versus €4.1B in FY2016, a compound +6.6%/yr. Reported net income was €732M in FY2020, compounding +8.9%/yr from FY2016.
Key figures
Market cap €17.3B · P/S ratio 2.23 · Dividend yield 0.7% · Net margin 13.7% · Return on equity 14.9% · Return on assets (EBIT) 9.4% · Operating margin 30.4% · Revenue (TTM) €7.7B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 28% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 3%, 0NZT screens richer than that median.
Fair Value models
All 25 models by family
Notify me when 0NZT reaches fair value
Put 0NZT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 34
Revenue & earnings trend
Watch 0NZT, get fair value alerts →
Compare UCB SA with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 626 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: UK Stocks
- Valuation of the UK market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is UCB SA (0NZT) overvalued or undervalued?
What is the fair value of 0NZT?
What is the quality score of 0NZT?
What is the price target for UCB SA (0NZT)?
What is the UCB SA stock forecast for 2026?
What is the revenue of UCB SA (0NZT)?
Does UCB SA pay a dividend?
What is the intrinsic value of UCB SA (0NZT)?
Is UCB SA stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 0NZT?
How much is UCB SA worth?
What do the bullish and bearish scenarios say about 0NZT?
How solid is the balance sheet of UCB SA (0NZT)?
How far is 0NZT from its 52-week high?
Which stocks are comparable to UCB SA?
Is UCB SA stock attractive at the current price?
How is the fair value of 0NZT calculated?
Is it still worth investing in stocks now?
What is the share price of UCB SA (0NZT)?
What should I pay attention to with UCB SA right now?
Key figures of UCB SA
How large is the market capitalisation of UCB SA (0NZT)?
What is the P/S ratio of UCB SA (0NZT)?
What is the dividend yield of UCB SA (0NZT)?
What is the net margin of UCB SA (0NZT)?
What is the return on equity of UCB SA (0NZT)?
What is the EBIT return on assets of UCB SA (0NZT)?
What is the operating margin of UCB SA (0NZT)?
How fast is revenue growing at UCB SA (0NZT)?
How fast are earnings growing at UCB SA (0NZT)?
Watch UCB SA in the live analysis
One click puts UCB SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.